What is an economic moat in the context of a company like Pfizer Inc.?

An economic moat refers to a company's structural advantage that protects its long-term profits and market share from competing firms. For Pfizer Inc., its established drug portfolio, strong brand recognition, and extensive research and development capabilities contribute to its wide moat. These advantages make it difficult for new entrants or existing competitors to capture its market position effectively, allowing it to sustain profitability over time.

What does "stock volatility" mean for an investor comparing companies like Pfizer Inc. and Moderna, Inc.?

Stock volatility measures how much a stock's price fluctuates over a period. High volatility, like Moderna, Inc.'s nearly 20%, indicates larger and more frequent price swings, potentially leading to higher risk but also higher potential returns. Conversely, low volatility, such as Pfizer Inc.'s 5.6%, suggests a more stable price, which might appeal to risk-averse investors seeking predictable returns.

What is a patent cliff and why is it significant for pharmaceutical companies?

A patent cliff occurs when a pharmaceutical company's key drugs lose their patent protection, opening the door for generic competitors to enter the market. This typically leads to a significant drop in revenue for the original drug. For companies like Pfizer Inc., facing a looming patent cliff on best-selling drugs means a critical period where they must innovate or acquire new products to offset potential revenue losses and maintain profitability.

How does a high dividend yield, such as that offered by Pfizer Inc., benefit investors?

A high dividend yield means that a company pays a substantial portion of its earnings back to shareholders as regular income. For investors in Pfizer Inc., its approximate 6.74% dividend yield provides a consistent cash flow, which can be particularly attractive for those seeking income-generating investments or looking to reinvest dividends. This can act as a cushion during market downturns and contribute to overall investment returns.

What does a company's current ratio, like Moderna, Inc.'s 3.93, indicate about its financial health?

The current ratio is a liquidity metric that assesses a company's ability to cover its short-term liabilities with its short-term assets. A ratio of 3.93 for Moderna, Inc. indicates that the company has nearly four times more current assets than current liabilities. This suggests a very strong liquidity position, meaning it is well-equipped to meet its immediate financial obligations without difficulty, which is a positive sign for investors.

Why is revenue growth, such as Moderna, Inc.'s projected 10% for 2026, important for an investment?

Revenue growth signifies a company's ability to expand its sales and market presence, often indicating a healthy and thriving business. Moderna, Inc.'s projection of 10% revenue growth for 2026, driven by pipeline advancements, suggests potential for future profitability and market share expansion. Sustained revenue growth is a key factor investors look for as it often correlates with increasing share value and long-term business viability.

What does a negative gross profit margin, observed in Moderna, Inc., suggest about a company's operations?

A negative gross profit margin, such as Moderna, Inc.'s -107.62%, means that the cost of goods sold (COGS) exceeds the revenue generated from sales. This indicates that the company is losing money on its core products before accounting for operating expenses, interest, or taxes. It often points to significant operational inefficiencies, high production costs, or severe pricing pressures, presenting a substantial challenge for achieving overall profitability.

How might the anticipated decline in COVID-19 business impact a company like Pfizer Inc.?

A significant anticipated decline in COVID-19 business, such as Pfizer Inc.'s projected 23% reduction, directly pressures future revenues and profitability. This impact necessitates the company to pivot its strategy, focusing on other drug portfolios or pipeline developments to compensate for the lost income. Investors would scrutinise how effectively Pfizer Inc. manages this transition and diversifies its revenue streams beyond its successful pandemic-related products.

What are "key catalysts" in the context of pharmaceutical companies like Moderna, Inc., and why are they important?

Key catalysts are specific events or developments that have the potential to significantly influence a company's stock price or future prospects. For Moderna, Inc., anticipated 2026 catalysts from its Phase III melanoma trial readout are crucial. A positive trial result could lead to regulatory approval, substantial revenue growth, and increased investor confidence, whereas a negative outcome could have the opposite effect, making these events highly significant.

What should a beginner understand about comparing the business models of Pfizer Inc. and Moderna, Inc.?

Beginners should recognise that Pfizer Inc. is a diversified, established pharmaceutical giant with a broad portfolio, facing challenges like patent expirations. Moderna, Inc. is a younger, more focused biotechnology company, relying heavily on its pipeline and new drug development, exhibiting higher growth potential but also greater risk. Understanding these fundamental differences in their operational structures and market positions is key to interpreting their financial metrics.

What is the main purpose of this comparison page for potential investors?

This page aims to provide a neutral and accessible comparison between Pfizer Inc. and Moderna, Inc., highlighting their distinct business models, financial performance, and market contexts. Its purpose is purely educational, helping users understand key differences and how to interpret financial information. It is crucial to remember that this content is not financial advice; users should conduct their own research and consult with a financial professional before making any investment decisions.

Pfizer vs Moderna

This page provides a detailed stock comparison between Pfizer Inc. and Moderna, Inc. We explore their distinct business models, analyse their financial performance, and examine their respective market contexts to help you understand the key differences. This analysis is presented in a neutral and accessible manner. Educational content, not financial advice.

This page provides a detailed stock comparison between Pfizer Inc. and Moderna, Inc. We explore their distinct business models, analyse their financial performance, and examine their respective market...

Comparison Snapshot

Key Financial Metrics

PFE

Metric

MRNA

$156.83B

Market Cap

$21.25B

5.32%

Potential Profit

-19.92%

Hold

Analyst Rating

Hold

Why It's Moving

Pfizer Stock Climbs Amid Strong Non-COVID Growth as Investors Eye Earnings Ahead

New and acquired products generated $10.2B in 2025 revenues, up 14% operationally, with double-digit growth expected in 2026 to fuel expansion beyond fading pandemic sales.
Non-COVID revenues grew 6% operationally last year, driven by blockbusters like Eliquis and Padcev, helping shares hold above key 50- and 200-day moving averages.
Recent sessions saw PFE gain 1.06% to $27.57 even as broader market dipped, highlighting investor confidence ahead of Q1 earnings forecast at $0.77 EPS and $13.83B revenue.

Sentiment:

🐃Bullish

Pfizer Stock Climbs Amid Strong Non-COVID Growth as Investors Eye Earnings Ahead

New and acquired products generated $10.2B in 2025 revenues, up 14% operationally, with double-digit growth expected in 2026 to fuel expansion beyond fading pandemic sales.
Non-COVID revenues grew 6% operationally last year, driven by blockbusters like Eliquis and Padcev, helping shares hold above key 50- and 200-day moving averages.
Recent sessions saw PFE gain 1.06% to $27.57 even as broader market dipped, highlighting investor confidence ahead of Q1 earnings forecast at $0.77 EPS and $13.83B revenue.

Sentiment:

🐃Bullish

Investment Analysis

Pfizer

PFE

Pros

Pfizer maintains a wide economic moat from its established drug portfolio and brand strength.
Pfizer offers a high dividend yield of around 6.74% to shareholders.
Pfizer exhibits low stock volatility of approximately 5.6%, reducing price fluctuation risk.

Considerations

Pfizer anticipates a 23% decline in its COVID-19 business, pressuring 2026 revenues.
Pfizer faces a looming patent cliff on key best-selling drugs, risking revenue losses.
Pfizer trimmed its FY2026 profit forecast to $2.80-$3 per share, below analyst estimates.

Moderna

MRNA

Pros

Moderna projects 10% revenue growth for 2026, driven by pipeline advancements.
Moderna holds a healthy current ratio of 3.93, ensuring strong liquidity coverage.
Moderna anticipates key 2026 catalysts from its Phase III melanoma trial readout.

Considerations

Moderna reports high stock volatility of nearly 20%, increasing investment risk.
Moderna experienced a 56% revenue decline over the last twelve months with negative EBITDA.
Moderna shows a negative gross profit margin of -107.62%, indicating ongoing unprofitability.

Related Market Insights

Pharma Giants: Why Healthcare Stocks Could Weather Any Storm

Invest in Pharma Giants: Discover healthcare stocks offering stability, growth, and recession resistance. Explore innovation & consistent demand in the $1.9T pharma market.

Aimee Silverwood | Financial Analyst

July 25, 2025

Read Insight

Buffett's $6 Billion Donation: The Stocks Set to Benefit

Discover how Warren Buffett's $6B donation creates unique investment opportunities in global health, agriculture & education. Invest via Nemo.

Aimee Silverwood | Financial Analyst

July 25, 2025

Read Insight

Related Market Insights

Pharma Giants: Why Healthcare Stocks Could Weather Any Storm

Invest in Pharma Giants: Discover healthcare stocks offering stability, growth, and recession resistance. Explore innovation & consistent demand in the $1.9T pharma market.

Aimee Silverwood | Financial Analyst

July 25, 2025

Read Insight

Buffett's $6 Billion Donation: The Stocks Set to Benefit

Discover how Warren Buffett's $6B donation creates unique investment opportunities in global health, agriculture & education. Invest via Nemo.

Aimee Silverwood | Financial Analyst

July 25, 2025

Read Insight

About Pfizer and Moderna

Pfizer (PFE)

Pfizer Inc (PFE) is a large-cap global pharmaceutical company known for developing, producing and commercialising medicines and vaccines across areas such as oncology, immunology, rare disease and infectious disease. The company’s scale, diversified portfolio and R&D pipeline are key considerations for investors: revenue is driven by established products, new approvals and licensing or royalty arrangements. Important risks include regulatory decisions, patent expiries, pricing pressure, competition and litigation — all of which can materially affect earnings. Pfizer has historically returned capital to shareholders via dividends and buybacks, but dividend levels and capital allocation depend on cash flow and strategic priorities. For those researching the stock, focus on upcoming clinical readouts, regulatory milestones, patent timelines, and quarterly financials. This is general educational information, not personal advice; pharmaceutical stocks can be volatile and past performance is not a reliable indicator of future results.

Moderna (MRNA)

Moderna, Inc. (MRNA) is a biotechnology company centred on messenger RNA (mRNA) technology, best known for its COVID‑19 vaccine. The company applies its platform to develop vaccines and therapeutics across infectious diseases (influenza, RSV, CMV) and oncology, aiming for faster design and scalable manufacturing. Investors should know Moderna’s prospects combine platform-driven upside with typical biotech risks: revenues can be lumpy, clinical trials are binary events, and regulatory approvals and competition (notably Pfizer/BioNTech) materially affect the outlook. The market capitalisation reflects the transition from pandemic-era demand to a broader commercial strategy. Moderna invests heavily in R&D and capacity, which can pressure margins in the near term but may support future growth if programmes succeed. This stock tends to be higher volatility and may suit investors with a longer timeframe and higher risk tolerance. This is general information, not personalised investment advice.

Pfizer (PFE) Next Earnings Date

Pfizer's next earnings report is expected on May 5, 2026, though the company has not officially confirmed this date and estimates range from April 27 through May 1, 2026. This release will cover first-quarter 2026 results, with analysts projecting earnings per share of approximately $0.74. The earnings call will provide management's discussion of financial performance and forward guidance for the remainder of the year.

Pfizer (PFE) Next Earnings Date

Pfizer's next earnings report is expected on May 5, 2026, though the company has not officially confirmed this date and estimates range from April 27 through May 1, 2026. This release will cover first-quarter 2026 results, with analysts projecting earnings per share of approximately $0.74. The earnings call will provide management's discussion of financial performance and forward guidance for the remainder of the year.

Which Baskets Do They Appear In?

Buffett's Billions: The Philanthropy Effect

Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.

Published: July 1, 2025

Explore Basket

Pharma

Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.

Published: May 6, 2025

Explore Basket

Which Baskets Do They Appear In?

Buffett's Billions: The Philanthropy Effect

Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.

Published: July 1, 2025

Explore Basket

Pharma

Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.

Published: May 6, 2025

Explore Basket

Pfizer vs Moderna

Comparison Snapshot

Why It's Moving

Pfizer Stock Climbs Amid Strong Non-COVID Growth as Investors Eye Earnings Ahead

Pfizer Stock Climbs Amid Strong Non-COVID Growth as Investors Eye Earnings Ahead

Investment Analysis

Pfizer

Pros

Considerations

Moderna

Pros

Considerations

Related Market Insights

Pharma Giants: Why Healthcare Stocks Could Weather Any Storm

Buffett's $6 Billion Donation: The Stocks Set to Benefit

Related Market Insights

Pharma Giants: Why Healthcare Stocks Could Weather Any Storm

Buffett's $6 Billion Donation: The Stocks Set to Benefit

About Pfizer and Moderna

Pfizer (PFE) Next Earnings Date

Pfizer (PFE) Next Earnings Date

Which Baskets Do They Appear In?

Buffett's Billions: The Philanthropy Effect

Pharma

Which Baskets Do They Appear In?

Buffett's Billions: The Philanthropy Effect

Pharma

Buy PFE or MRNA in Nemo

Zero Commission

Trusted & Regulated

6% Interest on Cash

Frequently asked questions

Comparison Snapshot

About Pfizer and Moderna